(NASDAQ: SLDB) Solid Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Solid Biosciences's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast SLDB's revenue for 2027 to be $4,628,926,926, with the lowest SLDB revenue forecast at $3,535,255,823, and the highest SLDB revenue forecast at $5,722,598,028. On average, 4 Wall Street analysts forecast SLDB's revenue for 2028 to be $9,358,304,953, with the lowest SLDB revenue forecast at $2,008,243,341, and the highest SLDB revenue forecast at $20,370,548,974.
In 2029, SLDB is forecast to generate $23,721,410,837 in revenue, with the lowest revenue forecast at $13,496,267,386 and the highest revenue forecast at $29,356,639,767.